After Falling -10.61% During The Past Week, Should You Still Buy Gossamer Bio Inc (NASDAQ: GOSS)?


Gossamer Bio Inc (NASDAQ:GOSS)’s traded shares stood at 1.07 million during the last session, with the company’s beta value hitting 1.70. At the close of trading, the stock’s price was $1.18, to imply an increase of 0.85% or $0.01 in intraday trading. The GOSS share’s 52-week high remains $1.88, putting it -59.32% down since that peak but still an impressive 61.86% since price per share fell to its 52-week low of $0.45. The company has a valuation of $266.18M, with an average of 1.32 million shares in intraday trading volume over the past 10 days and average of 1.09 million shares over the past 3 months.

Gossamer Bio Inc (NASDAQ:GOSS) trade information

After registering a 0.85% upside in the last session, Gossamer Bio Inc (GOSS) has traded red over the past five days. The stock hit a weekly high of 1.4000, jumping 0.85% in its intraday price action. The 5-day price performance for the stock is -10.61%, and -13.24% over 30 days. With these gigs, the year-to-date price performance is 29.32%. Short interest in Gossamer Bio Inc (NASDAQ:GOSS) saw shorts transact 11.09 million shares and set a 6.54 days time to cover.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Gossamer Bio Inc (GOSS) estimates and forecasts

Looking at statistics comparing Gossamer Bio Inc share performance against respective industry, we note that the company has outperformed competitors. Gossamer Bio Inc (GOSS) shares are 49.03% up over the last 6 months, with its year-to-date growth rate higher than industry average at 38.98% against 13.00%. Revenue is forecast to grow 65.40% this quarter before jumping 60.00% for the next one.

An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 11.99% for the past 5-year period. While 2024 is set for a 36.87% return in earnings, projections for the next 5 years are at 5.20% annually.

GOSS Dividends

Gossamer Bio Inc has its next earnings report out between May 07 and May 13. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Gossamer Bio Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.

Gossamer Bio Inc (NASDAQ:GOSS)’s Major holders

Gossamer Bio Inc insiders hold 2.26% of total outstanding shares, with institutional holders owning 93.30% of the shares at 95.46% float percentage. In total, 93.30% institutions holds shares in the company, led by HHLR Advisors, LTD. As of Jun 29, 2023, the company held over 4.97 million shares (or 2.21% of shares), all amounting to roughly $5.97 million.

The next major institution holding the largest number of shares is Millennium Management Llc with 4.21 million shares, or about 1.87% of shares outstanding. As of the market price on Jun 29, 2023, these shares were worth $5.05 million.

We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Gossamer Bio Inc (GOSS) shares. Going by data provided on Jun 29, 2023, Vanguard Total Stock Market Index Fund holds roughly 2.06 million shares. This is just over 0.91% of the total shares, with a market valuation of $2.47 million. Data from the same date shows that the other fund manager holds a little less at 1.12 million, or 0.50% of the shares, all valued at about 1.35 million.